Here's Why You Should Add AngioDynamics Stock to Your Portfolio

Zacks10-03

AngioDynamics, Inc. ANGO is well-poised for growth in the coming quarters, courtesy of its potential in NanoKnife System. The positive outlook for the stock is driven by NanoKnife's strong performance...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2472645150?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/8DL4Urc.vcUKmmhh1cXSgg--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/529a2bf6a4c772f942409efa3808349b","is_english":true,"pubTime":"2024-10-03 22:39","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2472645150","market":"us","top_or_hot":-1,"title":"Here's Why You Should Add AngioDynamics Stock to Your Portfolio","media":"Zacks","content":"<div>\n<p>AngioDynamics, Inc. ANGO is well-poised for growth in the coming quarters, courtesy of its potential in NanoKnife System. The positive outlook for the stock is driven by NanoKnife's strong performance...</p>\n\n<a href=\"https://finance.yahoo.com/news/heres-why-add-angiodynamics-stock-143900093.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Here's Why You Should Add AngioDynamics Stock to Your Portfolio</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHere's Why You Should Add AngioDynamics Stock to Your Portfolio\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-10-03 22:39 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/heres-why-add-angiodynamics-stock-143900093.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>AngioDynamics, Inc. ANGO is well-poised for growth in the coming quarters, courtesy of its potential in NanoKnife System. The positive outlook for the stock is driven by NanoKnife's strong performance...</p>\n\n<a href=\"https://finance.yahoo.com/news/heres-why-add-angiodynamics-stock-143900093.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ATIP","symbol_name":"ATI Physical Therapy Inc.","start_time":0,"source_url":"https://finance.yahoo.com/news/heres-why-add-angiodynamics-stock-143900093.html","article_id":"2472645150","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/8DL4Urc.vcUKmmhh1cXSgg--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/529a2bf6a4c772f942409efa3808349b"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2472645150","pubTimestamp":1727966340,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"AngioDynamics, Inc.ANGO is well-poised for growth in the coming quarters, courtesy of its potential in NanoKnife System. The positive outlook for the stock is driven by NanoKnife's strong performance and successful geographic expansion. However, pricing pressure and macroeconomic factors are concerns.Shares of this Zacks Rank #1  company have lost 2.4% year to date against theindustry's 8.3% growth. The S&P 500 Index has gained 20% in the said time frame.The company designs, manufactures and sells a wide range of medical, surgical, and diagnostic devices, which are generally utilized in minimally invasive, image-guided procedures and has a market capitalization of $310.85 million. It projects 7.6% earnings growth for fiscal 2026 and expects to maintain its strong performance. In the trailing four quarters, AngioDynamics surpassed earnings estimates thrice and missed on one occasion, the average beat being 28.61%.Our model projects AngioDynamics' revenues to witness a 5.9% CAGR from fis","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"ATIP":"ATI Physical Therapy Inc.","BK4082":"医疗保健设备","LU0130103400.USD":"Natixis Harris Associates Global Equity RA USD","AVAH":"Aveanna Healthcare Holdings Inc.","BK4185":"保健护理机构","LU0648000940.SGD":"Natixis Harris Associates Global Equity RA SGD","ANGO":"阿吉奥动态","LU1201861165.SGD":"Natixis Harris Associates Global Equity PA SGD","BK4539":"次新股","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","THC":"泰尼特","BK4196":"保健护理服务","LU0963586101.USD":"ALLIANZ GLOBAL SMALL CAP EQUITY \"AT\" ACC"},"translate_title":"这就是为什么您应该将AngioDynamics股票添加到您的投资组合中","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ANGO":1,"ATIP":1,"AVAH":1,"THC":1},"content_text":"AngioDynamics, Inc. ANGO is well-poised for growth in the coming quarters, courtesy of its potential in NanoKnife System. The positive outlook for the stock is driven by NanoKnife's strong performance and successful geographic expansion. However, pricing pressure and macroeconomic factors are concerns.\nShares of this Zacks Rank #1 (Strong Buy) company have lost 2.4% year to date against the industry's 8.3% growth. The S&P 500 Index has gained 20% in the said time frame.\nThe company designs, manufactures and sells a wide range of medical, surgical, and diagnostic devices, which are generally utilized in minimally invasive, image-guided procedures and has a market capitalization of $310.85 million. It projects 7.6% earnings growth for fiscal 2026 and expects to maintain its strong performance. In the trailing four quarters, AngioDynamics surpassed earnings estimates thrice and missed on one occasion, the average beat being 28.61%.\nImage Source: Zacks Investment Research\nFactors Favoring ANGO Stock\nBroad Product Line: AngioDynamics is a key player in minimally invasive medical devices, specializing in vascular access, surgery, peripheral vascular disease and oncology. Its product portfolio includes innovative solutions like Microwave Ablation, Radiofrequency Ablation (RFA), and the NanoKnife system, which is experiencing strong demand for tumor treatments.\nThe company is prioritizing research and development (R&D) investments to enhance its core technologies — AngioVac, Auryon, and NanoKnife — projecting a CAGR of 1.3% in R&D expenses from fiscal 2024 to 2027. Recent regulatory achievements, including a CE Mark approval in May and the FDA clearance for the AlphaVac F18 System, have enabled its commercial launch in the United States and CE Mark countries. These strategic initiatives position AngioDynamics for sustained growth in the medical device market.\nPotential in NanoKnife System: AngioDynamics is experiencing solid growth in its Med Tech segment, particularly with its NanoKnife product. The product received FDA clearance for soft tissue surgical ablation and was designated as a Breakthrough Device under the 21st Century Cures Act. In the fourth quarter of fiscal 2024, net sales of the Med Tech segment increased 11.3% year over year, bolstered by an 18% rise in NanoKnife disposable sales.\nManagement reported a 247.8% surge in capital sales, reflecting strong demand for disposables. It anticipates FDA clearance for NanoKnife in prostate ablation by the end of 2024, enabling a commercial launch and a specific CPT code for reimbursement clarity.\nOur model projects AngioDynamics' revenues to witness a 5.9% CAGR from fiscal 2024 to 2027, fueled by a 10.3% CAGR in the Med Tech segment. The company expects its bottom line to witness a 15.8% CAGR during the same period.\nStrong Geographic Expansion: AngioDynamics achieved 85.6% of fiscal 2024 net sales from the United States, up from 83.5% in 2023, driven by rising demand from medical professionals. International sales, accounting for 14.4%, grew 14%, bolstered by distributor relationships, including $1.4 million in sales to Iran. U.S. revenues increased 4.3% in the fourth quarter of 2024. The company anticipates steady growth at a CAGR of 2.2% in the United States and 0.5% internationally through 2027.\nDownsides\nPricing Pressure: AngioDynamics faces risks to its stock performance due to reliance on higher-priced products amid increased competition, healthcare provider consolidation, and declining reimbursement rates. Group purchasing organizations and integrated delivery networks further limit pricing flexibility, potentially hindering contract retention and impacting profitability and stock outlook\nMacroeconomic Concerns: AngioDynamics faces challenges from global economic conditions, including supply chain disruptions and weak financial results. In the fourth quarter of fiscal 2024, the gross margin dropped to 54.3%, with rising sales, marketing, and administrative costs. Growing costs and expenses could further strain profitability through fiscal 2027.\nEstimate Trend\nAngioDynamics is witnessing a positive earnings estimate revision trend for 2024. In the past 60 days, the Zacks Consensus Estimate for loss has narrowed from 47 cents to 41 cents per share.\nThe Zacks Consensus Estimate for the company’s third-quarter 2024 revenues and loss per share is pegged at $68.49 million and 15 cents, respectively, suggesting a 13% and 25% decline from the year-ago quarter’s reported numbers.\n\nAngioDynamics, Inc. Price\n\nAngioDynamics, Inc. price | AngioDynamics, Inc. Quote\n\nOther Key Picks\nSome other top-ranked stocks in the broader medical space are Tenet HealthCare (THC), ATI Physical Therapy (ATIP) and Aveanna Healthcare AVAH. While Tenet HealthCare sports a Zacks Rank #1, ATI Physical Therapy and Aveanna Healthcare carry a Zacks Rank #2 (Buy) each at present. You can see the complete list of today’s Zacks #1 Rank stocks here.\nTenet HealthCare has an estimated long-term growth rate of 18.3%. THC's earnings surpassed estimates in each of the trailing four quarters, with the average being 58.5%.\nTenet HealthCare has gained 119.9% compared with the industry's 48.6% growth year to date.\nATI Physical Therapy's earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 7.25%.\nATIP's shares have gained 5.5% year to date compared with the industry’s 18.6% growth.\nAveanna Healthcare's earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 47.5%.\nAVAH's shares have surged 104.5% year to date compared with the industry’s 15.7% growth.\nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\nAngioDynamics, Inc. (ANGO) : Free Stock Analysis Report\nTenet Healthcare Corporation (THC) : Free Stock Analysis Report\nAveanna Healthcare Holdings Inc. (AVAH) : Free Stock Analysis Report\nATI Physical Therapy, Inc. (ATIP) : Free Stock Analysis Report\nTo read this article on Zacks.com click here.\nZacks Investment Research","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2472645150"}